Skip to main content
    M

    MannKind Corp (MNKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.03 (-0.98%)

    Market Cap: $971.06M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    -33.02%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.01
    Range$-0.04 - $0.01
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.02-125.0%
    60d ago$0.02-125.0%
    30d ago$-0.010.0%
    7d ago$-0.010.0%
    Current$-0.01
    Revenue Consensus
    $110M
    Range$103M - $118M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.01 - $0.02
    4 analysts
    Revenue Consensus
    $119M
    Range$103M - $135M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.01---
    Jun 26
    Reported Aug 5
    		$-0.06$-0.02-200.00%Miss-220.0%
    Mar 26
    Reported May 6
    		$-0.02$0.01-398.51%Miss-150.0%
    Dec 25
    Reported Feb 26
    		$-0.05$-0.01-400.00%Miss-266.7%
    Sep 25
    Reported Nov 5
    		$0.03$0.01+200.00%Beat-25.0%
    Jun 25
    Reported Aug 6
    		$0.05$0.08-37.50%Miss+600.0%
    Mar 25
    Reported May 8
    		$0.04$0.06-33.33%Miss+0.0%
    Dec 24
    Reported Feb 26
    		$0.03$0.04-25.00%Miss+597.7%
    Sep 24
    Reported Nov 7
    		$0.04$0.03+33.33%Beat+300.0%
    Jun 24
    Reported Aug 7
    		$-0.01$0.01-200.00%Miss+50.0%
    Mar 24
    Reported May 8
    		$0.04$0.03+33.33%Beat+200.0%
    Dec 23
    Reported Feb 27
    		$0.00N/A-57.00%Miss+106.1%
    Sep 23
    Reported Nov 7
    		$0.01$-0.02+150.00%Beat+116.7%
    Jun 23
    Reported Aug 7
    		$-0.02$-0.04+50.00%Beat+81.8%
    Mar 23
    Reported May 9
    		$-0.04$-0.05+20.00%Beat+60.0%
    Dec 22
    Reported Feb 23
    		$-0.07$-0.06-16.67%Miss+36.4%
    Sep 22
    Reported Nov 8
    		$-0.06$-0.08+25.00%Beat-50.0%
    Jun 22
    Reported Aug 9
    		$-0.11$-0.09-22.22%Miss-120.0%
    Mar 22
    Reported May 5
    		$-0.10$-0.10+0.00%Beat-100.0%
    Dec 21
    Reported Feb 24
    		$-0.11$-0.07-57.14%Miss-83.3%
    Sep 21
    Reported Nov 9
    		$-0.04$-0.08+50.00%Beat+20.0%
    Jun 21
    Reported Aug 11
    		$-0.05$-0.04-25.00%Miss+0.0%
    Mar 21
    Reported May 12
    		$-0.05$-0.05+0.00%Beat-25.0%
    Dec 20
    Reported Feb 25
    		$-0.06$-0.04-50.00%Miss+14.3%
    Sep 20
    Reported Nov 4
    		$-0.05$-0.05+0.00%Beat+28.6%
    Jun 20
    Reported Aug 5
    		$-0.05$-0.06+16.67%Beat+28.6%
    Mar 20
    Reported May 6
    		$-0.04$-0.06+33.33%Beat+50.0%
    Dec 19
    Reported Feb 25
    		$-0.07$-0.08+12.50%Beat-16.7%
    Sep 19
    Reported Nov 6
    		$-0.07$-0.07+0.00%Beat+53.3%
    Jun 19
    Reported Aug 7
    		$-0.07$-0.08+12.50%Beat+58.8%
    Mar 19
    Reported May 7
    		$-0.08$-0.13+38.46%Beat+68.0%
    Dec 18
    Reported Feb 26
    		$-0.06N/A-127.27%Miss+78.6%
    Sep 18
    Reported Nov 1
    		$-0.15$-0.18+16.67%Beat+51.6%
    Jun 18
    Reported Aug 2
    		$-0.17$-0.20+15.00%Beat+50.0%
    Mar 18
    Reported May 9
    		$-0.25$-0.23-8.70%Miss-47.1%
    Dec 17
    Reported Feb 27
    		$-0.28$-0.29+3.45%Beat-47.4%
    Sep 17
    Reported Nov 7
    		$-0.31$-0.20-55.00%Miss-
    Jun 17
    Reported Aug 7
    		$-0.34$-0.23-47.83%Miss-
    Mar 17
    Reported May 10
    		$-0.17$0.12-241.67%Miss-
    Dec 16
    Reported Mar 16
    		$-0.19$-0.20+5.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-30.20EV/EBITDA70.41x
    Price/FCF-51.49xFCF Yield-1.94%
    Profitability
    Profit Margin-11.10%Operating Margin-0.76%
    ROE0.00%ROIC-1.56%
    Financial Health
    Debt/Equity-5.25xInterest Coverage0.83x
    Current Ratio1.72xQuick Ratio1.41x
    Trading Statistics
    Beta1.08Avg Volume5.51M
    52-Week High$6.5152-Week Low$2.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.46
    SMA 20$3.47
    SMA 50$3.77
    SMA 200$3.88
    EMA 10$3.32
    EMA 20$3.47
    EMA 50$3.65
    EMA 200$3.92

    MACD

    Line: -0.16Signal: -0.11Hist: -0.05

    ADX

    ADX: 20.6+DI: 17.7-DI: 32.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$4.02

    Bollinger Bands

    Upper Band$4.00
    Lower Band$2.93
    %B Position3076%(Upper)
    Band Width0.08

    RSI (14-Day)

    Neutral
    31.0

    Momentum Oscillators

    Stoch %K5.6
    Stoch %D8.4
    Williams %R-90.6
    ROC (10d)-22.6%
    Momentum-0.88
    CCI (20d)-144.2
    MFI (14d)47.1

    Volatility Measures

    ATR (14d)$0.21(7.1%)
    StdDev (20d)0.27
    Hist Vol74.4%(High)

    Volume Flow

    VWAP$3.01
    OBV-106.0M
    AD Line-129.1M
    CMF (20d)0.026

    Volume Metrics

    Avg Vol (20d)5.8M
    Vol Ratio1.4x
    VWMA (20d)$3.52

    Pivot Points

    R3$3.24
    R2$3.19
    R1$3.12
    Pivot Point$3.07
    S1$3.00
    S2$2.95
    S3$2.88

    Advanced Oscillators

    TSI-22.21
    Ultimate Osc37.3
    KST-95.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$109.37M$90.17M$111.95M$82.13M$76.53M$78.35M$76.78M$70.08M$72.39M$66.26M$58.47M$51.25M
    Cost of Revenue$29.54M$17.47M$29.67M$20.20M$20.57M$17.52M$19.60M$18.02M$20.38M$18.60M$18.07M$14.25M
    Gross Profit$79.83M$72.70M$82.28M$61.93M$55.96M$60.84M$57.17M$52.06M$52.01M$47.66M$40.41M$37.00M
    Operating Expenses$80.18M$74.36M$89.97M$43.03M$50.66M$38.55M$30.68M$39.30M$35.40M$30.94M$32.55M$31.90M
    R&D$18.00M$17.23M$27.59M$14.06M$13.68M$11.02M$11.14M$12.93M$11.82M$10.01M$9.24M$9.99M
    SG&A$58.30M$54.09M$58.41M$29.09M$31.62M$25.01M$23.97M$23.92M$24.11M$22.33M$20.54M$23.98M
    Operating Income$-350,000$-1,667,000$-7,687,000$18.90M$5.30M$22.29M$26.50M$12.76M$16.61M$16.72M$7.86M$5.10M
    Interest Income$1.02M$1.43M$1.64M$2.63M$1.83M$1.96M$2.83M$3.18M$3.18M$3.43M$1.73M$1.58M
    Interest Expense$14.82M$13.35M$13.87M$7.33M$6.19M$10.63M$20.88M$8.36M$19.93M$9.26M$5.36M$5.27M
    Income Before Tax$-19,138,000$-16,366,000$-20,931,000$7.78M$940,000$13.62M$8.45M$12.87M$-1,691,000$10.89M$2.96M$1.72M
    Income Tax Expense$-106,000$253,000$-4,983,000$-204,000$272,000$459,000$1.02M$1.32M$323,000$264,000$1.56M$0
    Net Income$-19,032,000$-16,619,000$-15,948,000$7.99M$668,000$13.16M$7.42M$11.55M$-2,014,000$10.63M$1.40M$1.72M
    EBITDA$1.47M$2.39M$-1,782,000$15.45M$8.57M$24.51M$29.50M$21.08M$17.52M$18.91M$8.65M$7.40M
    EBIT$-5,342,000$-4,444,000$-7,687,000$12.49M$5.30M$22.29M$26.50M$18.05M$15.06M$16.72M$6.59M$5.42M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MNKD

    News

    MannKind Corporation (MNKD) Stock Price, News, Quote & History

    This article provides comprehensive financial information for MannKind Corporation (MNKD), including its stock price, historical data, key performance indicators...

    Yahoo! Finance Canada•10/15/26•Neutral

    MannKind to Participate in the Chardan Healthcare Conference

    MannKind Corporation announced that its CEO, Michael Castagna, will participate in a panel discussion at the Chardan Healthcare Conference on October 20...

    GlobeNewswire•10/14/26•Somewhat-Bullish

    MannKind to Participate in the Chardan Healthcare Conference

    MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference. The panel will take place...

    GlobeNewswire•10/14/26•Neutral

    MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026

    MannKind Corporation announced new clinical data at the HFSA 2026 meeting for its Furoscix ReadyFlow autoinjector, showing it delivers IV-equivalent diuresis across various injection sites. The autoinjector...

    Quiver Quantitative•10/10/26•Bullish

    A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

    MannKind announced new clinical data for its Furoscix ReadyFlow autoinjector, showing comparable urine output and total drug exposure to intravenous furosemide for treating fluid overload in heart failure and chronic...

    Stock Titan•10/10/26•Bullish

    MNKD Valuation and Fair Value

    P/E
    -30.2x
    Forward P/E
    25.7x
    EV/EBITDA
    70.4x
    P/FCF
    -51.5x
    PEG
    4.4x
    P/B
    -13.9x
    See GNG's fair value

    MNKD Profitability: Margins, ROIC and FCF

    Gross margin
    75.4%
    Operating margin
    -0.8%
    Net margin
    -11.1%
    ROIC
    -1.6%
    ROE
    0.0%
    FCF margin
    -4.6%
    FCF yield
    -1.9%

    MNKD Competitors

    CompanyTicker
    Savara IncSVRA
    Quidel CorporationQDEL
    Ventyx Biosciences IncVTYX
    Beta Bionics, Inc. Common StockBBNX
    Castle Biosciences IncCSTL
    Theravance Biopharma IncTBPH
    Harrow Health IncHROW
    MoonLake ImmunotherapeuticsMLTX

    Sector: Healthcare

    MNKD Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    MNKD Bull Case vs Bear Case

    Bull case

    • MNKD grew quarterly revenue 42.9% year over year.
    • 87.5% of MNKD's analyst ratings are Buy or Strong Buy.

    Bear case

    • MNKD has a -11.1% net profit margin.
    • MNKD beat EPS estimates in 25.0% of its last 8 reported quarters.

    MNKD Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -107.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About MNKD

    Does MNKD pay dividends?

    MannKind Corp (MNKD) does not currently pay a regular dividend.

    What is MNKD's market cap?

    MannKind Corp (MNKD) has a market capitalization of $971.06M with a current stock price of $3.02.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In